Regencell Bioscience Holdings Limited (RGC)

NASDAQ: RGC · Real-Time Price · USD

520.00

+18.38 (3.66%)

At close: May 28, 2025, 4:00 PM

517.90

-2.10 (-0.40%)

After-hours: May 28, 2025, 4:36 PM EDT

RGC Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	2019
Selling, General & Admin	3.78	4.8	5.11	0.94	0.43	Upgrade
Research & Development	0.95	1.47	2.51	0.44	0.39	Upgrade
Operating Expenses	4.74	6.27	7.62	1.38	0.81	Upgrade
Operating Income	-4.74	-6.27	-7.62	-1.38	-0.81	Upgrade
EBT Excluding Unusual Items	-4.74	-6.27	-7.62	-1.38	-0.81	Upgrade
Other Unusual Items	0.37	0.21	0.02	0.03	-	Upgrade
Pretax Income	-4.36	-6.06	-7.59	-1.35	-0.81	Upgrade
Earnings From Continuing Operations	-4.36	-6.06	-7.59	-1.35	-0.81	Upgrade
Minority Interest in Earnings	0.06	0.19	0.15	-	-	Upgrade
Net Income	-4.3	-5.87	-7.45	-1.35	-0.81	Upgrade
Net Income to Common	-4.3	-5.87	-7.45	-1.35	-0.81	Upgrade
Shares Outstanding (Basic)	13	13	13	10	10	Upgrade
Shares Outstanding (Diluted)	13	13	13	10	10	Upgrade
Shares Change (YoY)	-	1.62%	28.06%	-	-	Upgrade
EPS (Basic)	-0.33	-0.45	-0.58	-0.13	-0.08	Upgrade
EPS (Diluted)	-0.33	-0.45	-0.58	-0.13	-0.08	Upgrade
Free Cash Flow	-4.01	-4.99	-6.05	-0.77	-0.84	Upgrade
Free Cash Flow Per Share	-0.31	-0.38	-0.47	-0.08	-0.08	Upgrade
EBITDA	-4.43	-5.98	-7.47	-1.35	-0.8	Upgrade
D&A For EBITDA	0.31	0.29	0.15	0.03	0.01	Upgrade
EBIT	-4.74	-6.27	-7.62	-1.38	-0.81	Upgrade
Advertising Expenses	1	0.03	0.03	-	-	Upgrade

Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q